Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Besser MJ, et al. Among authors: yerushalmi r. Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20. Clin Cancer Res. 2013. PMID: 23690483 Clinical Trial.
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Exp Hematol. 2007 Apr;35(4):534-40. doi: 10.1016/j.exphem.2007.01.043. Exp Hematol. 2007. PMID: 17379063 Free article. Clinical Trial.
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Leukemia. 2007 Oct;21(10):2109-16. doi: 10.1038/sj.leu.2404886. Epub 2007 Aug 9. Leukemia. 2007. PMID: 17690701
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Bone Marrow Transplant. 2008 Feb;41(4):355-61. doi: 10.1038/sj.bmt.1705919. Epub 2007 Nov 19. Bone Marrow Transplant. 2008. PMID: 18026153 Clinical Trial.
Cord blood stem cells for hematopoietic transplantation.
Stanevsky A, Shimoni A, Yerushalmi R, Nagler A. Stanevsky A, et al. Among authors: yerushalmi r. Stem Cell Rev Rep. 2011 Jun;7(2):425-33. doi: 10.1007/s12015-010-9183-9. Stem Cell Rev Rep. 2011. PMID: 20809256 Review.
Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit.
Goldstein G, Elhasid R, Bielorai B, Shimoni A, Yerushalmi R, Kassis I, Nagler A. Goldstein G, et al. Among authors: yerushalmi r. Leuk Lymphoma. 2011 Apr;52(4):635-41. doi: 10.3109/10428194.2010.548109. Epub 2011 Feb 21. Leuk Lymphoma. 2011. PMID: 21338286
219 results